Form 4: BVF Partners and Affiliates Report Significant Holdings and New Option Grant in Olema Pharmaceuticals

BVF Partners L.P. and its affiliated entities, along with Mark N. Lampert, have filed a Form 4 detailing their substantial beneficial ownership in Olema Pharmaceuticals, Inc., including common stock, pre-funded warrants, and newly acquired stock options.

Summary

• The filing reports the beneficial ownership of Olema Pharmaceuticals, Inc. (OLMA) securities by BVF Partners L.P. and a group of related entities and individuals, including Mark N. Lampert.
• The reporting persons are identified as Directors and 10% Owners, with their director status attributed to 'deputization' through Gorjan Hrustanovic, a board member who is obligated to transfer economic benefits from his options to Partners.
• As of the reporting date, the group beneficially owns a total of 5,107,069 shares of common stock directly and indirectly.
• They also hold 6,254,882 pre-funded warrants, each exercisable for one share of common stock at a par value of $0.0001, subject to a 9.99% ownership limitation upon exercise.
• A new grant of 24,150 stock options was acquired on June 11, 2025, with an exercise price of $4.08 and an expiration date of June 11, 2035.
• These new options will vest in 12 equal monthly installments starting June 11, 2025, or fully vest at the next annual meeting if not fully vested by then, contingent on Dr. Hrustanovic's continuous service.
• Additionally, the group holds 152,120 previously granted stock options with various exercise prices ranging from $3.61 to $27.66, all of which are fully vested.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing insider ownership and a new option grant. It does not contain information that would significantly alter the perceived value or risk of the company, thus maintaining a neutral sentiment.

Positives

• The acquisition of 24,150 new stock options by a director, even with an economic benefit transfer agreement, indicates continued alignment of interests with the company's performance.

Risks

• The pre-funded warrants have a limitation preventing the holder from exercising any portion that would result in ownership exceeding 9.99% of the outstanding common stock immediately after exercise, which could limit full conversion if the group's total beneficial ownership approaches this threshold.

Future Outlook

The newly acquired stock options for Gorjan Hrustanovic are set to vest in 12 equal monthly installments starting June 11, 2025, or fully vest at the company's next annual meeting if not fully vested by that date, subject to his continuous service.

Management Comments

• The Reporting Persons are deemed to be directors by deputization of Olema Pharmaceuticals, Inc. because Gorjan Hrustanovic, a member of Partners, serves on the Board of Directors and has an agreement to transfer the economic benefit from his exercised securities to Partners.
• Each of the Reporting Persons disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

Industry Context

This Form 4 filing is a routine disclosure for a biotechnology company, indicating the ownership structure and insider transactions of a significant institutional investor group. Such filings are common in the biotech sector where specialized funds like BVF Partners often take substantial stakes and board representation.

Management Changes

Corporate Governance

Related Party Transactions

• An agreement exists between Partners (part of the reporting group) and Gorjan Hrustanovic, a director of Olema Pharmaceuticals, where Dr. Hrustanovic is obligated to transfer the economic benefit received upon the sale of shares issuable from his stock options to Partners. This constitutes a related party arrangement.

Stakeholder Impact

• Shareholders: Provides transparency on the significant ownership stake and ongoing equity-based incentives of a major institutional investor group and its affiliated director.
• Management: Highlights the compensation structure for a board member and the influence of a key investor group.

Next Steps

• The newly granted stock options will continue to vest in monthly installments from June 11, 2025, or fully vest at the next annual meeting of stockholders.
• The pre-funded warrants and existing stock options remain exercisable, subject to their terms and conditions.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, SEC Form 4, Beneficial Ownership, Insider Holdings, Stock Options, Pre-Funded Warrants, BVF Partners, Director by Deputization, Equity Securities